Epidemiological Study on Malignancy Complicated With Renal Injury
1 other identifier
observational
30,000
0 countries
N/A
Brief Summary
The epidemiological study of tumor complicated with kidney disease can clarify the prevalence and risk factors of renal injury when malignant tumor is diagnosed, and understand the impact of malignant tumor complicated with renal injury on survival time. This study will bring enlightenment to clinicians, discover high-risk factors in time, and try to avoid renal damage factors in diagnosis and treatment. Early diagnosis and early treatment can partially terminate the progress of renal injury, avoid the suspension of treatment due to renal reasons, and avoid the occurrence of end-stage renal failure (ESRD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 23, 2022
CompletedFirst Posted
Study publicly available on registry
May 26, 2022
CompletedStudy Start
First participant enrolled
December 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedMay 26, 2022
May 1, 2022
2 years
May 23, 2022
May 23, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
survival
survival time
3 years
Study Arms (2)
Normal renal function group
Observe survival time
Renal dysfunction group
Observe survival time
Eligibility Criteria
Patients initially diagnosed with malignancy in Shanghai Renji Hospital from July 2017 to June 2021
You may qualify if:
- Malignancy confirmed by pathology.
- Between 18-80 years old, regardless of gender; Patients initially diagnosed with malignant tumors in our hospital from July 2017 to June 2021; Waiver of informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- RenJi Hospitallead
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Attending
Study Record Dates
First Submitted
May 23, 2022
First Posted
May 26, 2022
Study Start
December 1, 2022
Primary Completion
December 1, 2024
Study Completion
December 1, 2024
Last Updated
May 26, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share